CHM.AX falls 50.00% to A$0.001 on ASX after hours 09 Apr 2026: key targets

CHM.AX stock dropped 50.00% in after hours trade on 09 Apr 2026, closing at A$0.001 on the ASX. The move made Chimeric Therapeutics Limited (CHM.AX) one of the top losers on the ASX session, with 8,200,000 shares trading and market cap near A$4,418,704.00.

This note unpacks the drivers behind the sell-off, company fundamentals, technical signals, and Meyka AI’s model-based price view. We present clear price targets and risk points for investors tracking CHM.AX stock in Australia’s biotechnology sector.

CHM.AX stock price action and liquidity

Chimeric Therapeutics Limited (CHM.AX) fell from an open of A$0.002 to a day low of A$0.001, a 50.00% one-day decline, on after hours trading. Volume was 8,200,000 versus average volume 4,046,901, giving a relative volume of 2.03 and signalling heavy selling pressure. Shares outstanding stand at 4,418,703,619, and the market cap is about A$4,418,704.00, highlighting the stock’s microcap liquidity risk on the ASX in AUD.

Drivers behind the fall and sector context for CHM.AX stock

Chimeric Therapeutics operates clinical-stage cell therapies in oncology, including CHM 0201 and CHM 1101. The biotech sector has lagged year-to-date and healthcare performance shows mixed flows in April. Recent market chatter compares peers and diagnostics providers; see a sector comparison note at Investing.com for context. No company-specific earnings release accompanied the drop, so the move appears liquidity and sentiment driven against a weak biotech tape.

Fundamentals and valuation metrics for CHM.AX stock

Latest reported price-to-sales is 1.24, EPS is -0.01 and trailing PE reads -0.10, reflecting reported losses. Price averages are A$0.00202 (50-day) and A$0.00298 (200-day). Current ratio is 0.69 and cash per share is 0.000768, showing tight short-term liquidity. These metrics underline a speculative equity with negative earnings and stretched working capital.

Meyka AI grade and technical snapshot for CHM.AX stock

Meyka AI rates CHM.AX with a score out of 100: Score: 66.14 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Technically, RSI is 42.29, ADX 42.00 (strong trend), CCI -103.70 (oversold) and ROC -50.00%, which aligns with the sharp one-day decline and elevated volatility.

Risk factors, catalysts and trading strategy for CHM.AX stock

Primary risks include trial outcomes, cash runway, and microcap illiquidity. Key near-term catalysts are clinical updates and the next earnings notice expected 2026-08-28. Given the stock’s A$0.001 price and high share count, investors should size positions carefully and use limit orders. Sector rotation or positive clinical readouts would be the main upside triggers.

Technical outlook and short-term targets for CHM.AX stock

Short-term technical support sits at A$0.001 and resistance near the 50-day average A$0.00202. A conservative near-term price target for selective buyers is A$0.005 (implied upside +400.00% from A$0.001), while a downside stop could be A$0.0005 (implied downside -50.00%). Use these targets with strict risk limits; penny biotech moves can be binary.

Final Thoughts

CHM.AX stock’s 50.00% after-hours drop to A$0.001 on 09 Apr 2026 highlights the microcap volatility in ASX biotechnology names. Fundamentals show negative EPS -0.01, a negative PE -0.10, and tight short-term liquidity with current ratio 0.69. Meyka AI’s model and technicals point to high downside risk but also asymmetric upside if clinical catalysts re-emerge.

Meyka AI’s forecast model projects a baseline recovery scenario near A$0.005 and a downside stress level near A$0.0005. Against the current price of A$0.001, that implies an upside of +400.00% to the recovery target and a downside of -50.00% to the stress level. Forecasts are model-based projections and not guarantees. For active traders, we recommend tight position sizing, clear stop levels, and monitoring clinical timelines. For longer-term investors, wait for clinical readouts and clearer cash runway disclosure before increasing exposure to CHM.AX stock.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.